Helix BioPharma is expected to report a small per-share loss, but the estimate comes from just one analyst. The company has matched estimates in the examples provided, not beaten them, so there’s little basis for a confident forecast.
Helix BioPharma Corp. (HBP.TO) is scheduled to report results after markets close on October 29, 2026, for the fiscal period ended July 31. The calendar lists estimated earnings per share (EPS) of -C$0.02 and revenue of C$0, both based on one analyst. That’s a very limited sample, not a broad consensus. Helix has no EPS beats in its last four reported quarters with comparable data. Its longer history includes 11 actual-versus-estimate comparisons. Follow the company on the HBP stock page as the report approaches.
Recent earnings trend
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$75.61M
52W high
$2.60
52W low
$0.82
1W change
+1.02%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 152.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+152.5% Upside
Current Price
C$0.99
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
123.4%
Annualized
90-Day Vol
89.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.93 | C$0.61 – C$1.43 |
| 60 trading days | C$0.88 | C$0.48 – C$1.61 |
| 90 trading days | C$0.83 | C$0.40 – C$1.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-04-30 | 2026-06-15 | -0.0088 | — | — |
| 2026-01-31 | 2026-03-16 | -0.0091 | — | — |
| 2025-10-31 | 2026-01-13 | -0.0133 | — | — |
| 2025-07-31 | 2025-10-30 | -0.0128 | — | — |
| 2025-04-30 | 2025-07-31 | -0.0291 | — | — |
| 2025-01-31 | 2025-03-14 | -0.0275 | — | — |
Advertisement
Investor takeaway: The current estimate is a loss of C$0.02 per share, unchanged over the past 30 days. But with only one analyst contributing, it’s a fragile forecast. Helix has not beaten estimates in its last four comparable quarters, and the historical examples provided show results matching estimates. Treat the EPS figure as a reference point, not a reliable prediction. The financial statements and any update on clinical development will matter more than whether the company beats or misses this estimate.
C$0.02 loss per share is the estimate
One analyst expects EPS of -C$0.02 for the period ended July 31, 2026. The estimate hasn’t changed in the past 30 days. Helix has no beats in its last four comparable quarters, but the small analyst sample and limited calendar data don’t support a firm prediction about whether it will beat or miss.
Bull case
The EPS estimate has held at -C$0.02, and the historical comparisons provided show Helix matching estimates rather than falling short. Recent company announcements point to a focus on clinical development. In August 2026, Helix appointed a chief medical officer and described planned work involving L-DOS47 and pembrolizumab, as well as development of LEUMUNA. If the report offers concrete progress or useful financial details, investors will have more to consider than the limited calendar estimates.
Bear case
Just one analyst contributed to the estimate, and the revenue consensus is C$0. Neither figure offers a strong benchmark for judging the quarter. Helix is still loss-making, with trailing 12-month EPS of -C$0.04. Its shares closed at C$0.99, below the 50-day average of C$1.39 and the 200-day average of C$1.66. Clinical development can take time and funding before it generates commercial revenue, and the information available doesn’t show that this report will change that outlook.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
